1Bergrem H, Danielson BG, Eckardt KU, et al. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Erythropoietin: molecular physiology and clinical application [M] . New York: Marcel Dekker, 1993: 266.
2Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins [J]. J Am Soc Nephrol,2002, 13: 2381.
3Casadevall N. PRCA and antierythropoietin antibodies in patients treated with recombinant erythropoietin [J] .N Engl J Med, 2002, 346: 265.
4Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant [J] . Erythropoietin, 2002,346: 469.
5Sasaki H, Bothner B, Dell A, et al. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA[ J] . J Biol Chen, 1987, 262: 12059.
6Storring PL, Tiplady R J, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties [ J] . Br J Haematol, 1998, 100: 79.
7Besarab A, Reyes CM, Homberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients [J] . Am J KidneyDis, 2002, 40: 439.
8National Kidney Foundation-K/DOQI. Clinical practice guidelines for the management of anemia of chronic renal failure [J] . Am J Kid Dis, 2001, Suppl5: S182.
